Bone remodeling biomarkers of periodontal disease in saliva

Journal of Periodontology

Volumn 79, Issue 10, 2008, Pages 1913-1919

  Frodge, Brandon D ^a   Ebersole, Jeffrey L ^b   Kryscio, Richard J ^c   Thomas, Mark V ^b   Miller, Craig S ^b,c  

^a University of Kentucky ^*

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY COLLEGE OF DENTISTRY   (United States)

Author keywords

C telopeptide pyridinoline; Periodontal diseases; Receptor activator of nuclear factor kappa B ligand; Tumor necrosis factor alpha

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 1; COLLAGEN TYPE I TRIMERIC CROSS LINKED PEPTIDE; COLLAGEN TYPE I TRIMERIC CROSS-LINKED PEPTIDE; OSTEOCLAST DIFFERENTIATION FACTOR; PEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BONE REMODELING; CASE CONTROL STUDY; CHEMISTRY; CLASSIFICATION; COMPARATIVE STUDY; FEMALE; GINGIVA BLEEDING; HUMAN; MALE; MIDDLE AGED; OSTEOLYSIS; PERIODONTAL DISEASE; PERIODONTICS; PERIODONTITIS; PHYSIOLOGY; SALIVA;

ADULT; ALVEOLAR BONE LOSS; BIOLOGICAL MARKERS; BONE REMODELING; CASE-CONTROL STUDIES; COLLAGEN TYPE I; FEMALE; GINGIVAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PEPTIDES; PERIODONTAL ATTACHMENT LOSS; PERIODONTAL INDEX; PERIODONTAL POCKET; PERIODONTITIS; RANK LIGAND; SALIVA; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 53549100181     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2008.080070     Document Type: Article

References (70)

1. Albandar JM, Brunelle JA, Kingman A. Destructive periodontal disease in adults 30 years of age and older in the United States, 1988-1994. J Periodontol 1999;70:13-29 (erratum 1999;70:351).
2. Petersen PE, Ogawa H. Strengthening the prevention of periodontal disease: The WHO approach. J Periodontol 2005;76:2187-2193.
3. U.S. Census Bureau. U.S. interim projections by age, sex, race, and Hispanic origin. Available at http://www.census.gov/ipc/www/usinterimproj/. Accessed March 18, 2008.
4. Hand JS, Hunt RJ, Kohout FJ. Five-year incidence of tooth loss in Iowans aged 65 and older. Community Dent Oral Epidemiol 1991;19:48-51.
5. Beck JD, Sharp T, Koch GG, Offenbacher S. A 5-year study of attachment loss and tooth loss in community-dwelling older adults. J Periodontal Res 1997;32:516-523.
6. Brown LF, Beck JD, Rozier RG. Incidence of attachment loss in community-dwelling older adults. J Periodontol 1994;65:316-323.
7. Thomson WM, Slade GD, Beck JD, Elter JR, Spencer AJ, Chalmers JM. Incidence of periodontal attachment loss over 5 years among older South Australians. J Clin Periodontol 2004;31:119-125.
8. Brown LJ, Brunelle JA, Kingman A. Periodontal status in the United States, 1988-1991: Prevalence, extent, and demographic variation. J Dent Res 1996;75(Spec. Issue):672-683.
9. Virally M, Blicklé JF, Girard J, Halimi S, Simon D, Guillausseau PJ. Type 2 diabetes mellitus: Epidemiology, pathophysiology, unmet needs and therapeutical perspectives. Diabetes Metab 2007;33:231-244.
10. Geiss LS, Pan L, Cadwell B, Gregg EW, Benjamin SM, Engelgau MM. Changes in incidence of diabetes in U.S. adults, 1997-2003. Am J Prev Med 2006;30:371-377.
11. Beck JD, Offenbacher S. Systemic effects of periodontitis: Epidemiology of periodontal disease and cardiovascular disease. J Periodontol 2005;76:2089-2100.
12. Genco RJ, Trevisan M, Wu T, Beck JD. Periodontal disease and risk of coronary heart disease. JAMA 2001;285:40-41.
13. Seymour GJ, Ford PJ, Cullinan MP, Leishman S, Yamazaki K. Relationship between periodontal infections and systemic disease. Clin Microbiol Infect 2007;13(Suppl. 4):3-10.
14. Mealey BL, Oates TW. Diabetes mellitus and periodontal diseases. J Periodontol 2006;77:1289-1303.
15. American Academy of Periodontology. Diagnosis of periodontal diseases (position paper). J Periodontol 2003;74:1237-1247.
16. Fox PC. Salivary monitoring in oral diseases. Ann N Y Acad Sci 1993;694:234-237.
17. Kaufman E, Lamster IB. Analysis of saliva for periodontal diagnosis - A review. J Clin Periodontol 2000;27:453-465.
18. Kaufman E, Lamster IB. The diagnostic applications of saliva - A review. Crit Rev Oral Biol Med 2002;13:197-212.
19. Lamster IB, Grbic JT. Diagnosis of periodontal disease based on analysis of the host response. Periodontol 2000 1995;7:83-99.
20. Seymour GJ, Gemmell E. Cytokines in periodontal disease: Where to from here? Acta Odontol Scand 2001;59:167-173.
21. Lamster IB, Kaufman E, Grbic JT, Winston LJ, Singer RE. Beta-glucuronidase activity in saliva: Relationship to clinical periodontal parameters. J Periodontol 2003;74:353-359.
22. Pederson ED, Stanke SR, Whitener SJ, Sebastiani PT, Lamberts BL, Turner DW. Salivary levels of alpha 2-macroglobulin, alpha 1-antitrypsin, C-reactive protein, cathepsin G and elastase in humans with or without destructive periodontal disease. Arch Oral Biol 1995;40:1151-1155.
23. Christodoulides N, Mohanty S, Miller CS, et al. Application of microchip assay system for the measurement of C-reactive protein in human saliva. Lab Chip 2005;5:261-269.
24. Miller CS, King CP Jr., Langub MC, Kryscio RJ, Thomas MV. Salivary biomarkers of existing periodontal disease: A cross-sectional study. J Am Dent Assoc 2006;137:322-329.
25. Christodoulides N, Floriano PN, Miller CS, et al. Labon-a-chip methods for point-of-care measurements of salivary biomarkers of periodontitis. Ann N Y Acad Sci 2007;1098:411-428.
26. Scannapieco FA, Ng P, Hovey K, Hausmann E, Hutson A, Wactawski-Wende J. Salivary biomarkers associated with alveolar bone loss. Ann N Y Acad Sci 2007;1098:496-497.
27. Ng PY, Donley M, Hausmann E, Hutson AD, Rossomando EF, Scannapieco FA. Candidate salivary biomarkers associated with alveolar bone loss: Cross-sectional and in vitro studies. FEMS Immunol Med Microbiol 2007;49:252-260.
28. Taubman MA, Valverde P, Han X, Kawai T. Immune response: The key to bone resorption in periodontal disease. J Periodontol 2005;76:2033-2041.
29. Armitage GC. Periodontal diagnoses and classification of periodontal diseases. Periodontol 2000 2004;34:9-21.
30. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol 1999;4:1-6.
31. Navazesh M. Methods for collecting saliva. Ann N Y Acad Sci 1993;694:72-77.
32. Cecchettin M, Bellometti S, Cremonesi G, Solimeno LP, Torri G. Metabolic and bone effects after administration of ipriflavone and salmon calcitonin in postmenopausal osteoporosis. Biomed Pharmacother 1995;49:465-468.
33. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137-1141.
34. Worsfold M, Powell DE, Jones TJ, Davie MW. Assessment of urinary bone markers for monitoring treatment of osteoporosis. Clin Chem 2004;50:2263-2270.
35. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002;2:389-406.
36. Mogi M, Otogoto J, Ota N, Togari A. Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis. J Dent Res 2004;83:166-169.
37. Vernal R, Chaparro A, Graumann R, Puente J, Valenzuela MA, Gamonal J. Levels of cytokine receptor activator of nuclear factor kappaB ligand in gingival crevicular fluid in untreated chronic periodontitis patients. J Periodontol 2004;75:1586-1591.
38. Lu HK, Chen YL, Chang HC, Li CL, Kuo MY. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis. J Periodontal Res 2006;41:354-360.
39. Bostanci N, Ilgenli T, Emingil G, et al. Gingival crevicular fluid levels of RANKL and OPG in periodontal diseases: Implications of their relative ratio. J Clin Periodontol 2007;34:370-376.
40. Mogi M, Otogoto J. Expression of cathepsin-K in gingival crevicular fluid of patients with periodontitis. Arch Oral Biol 2007;52:894-898.
41. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-495.
42. Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 2007;9(Suppl. 1):S1.
43. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-176.
44. Monov G, Strbac GD, Baron M, Kandler B, Watzek G, Gruber R. Soluble RANKL in crevicular fluid of dental implants: A pilot study. Clin Implant Dent Relat Res 2006;8:135-141.
45. Giannobile WV, Al-Shammari KF, Sarment DP. Matrix molecules and growth factors as indicators of periodontal disease activity. Periodontol 2000 2003;31:125-134.
46. Risteli L, Risteli J. Biochemical markers of bone metabolism. Ann Med 1993;25:385-393.
47. Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999;402:304-309.
48. Alvarez L, Guanabens N, Peris P, et al. Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res 1995;10:458-465.
49. Mazzaferro S, Chicca S, Pasquali M, et al. Changes in bone turnover after parathyroidectomy in dialysis patients: Role of calcitriol administration. Nephrol Dial Transplant 2000;15:877-882.
50. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-361.
51. Sakurai A, Okahashi N, Nakagawa I, et al. Streptococcus pyogenes infection induces septic arthritis with increased production of the receptor activator of the NF-kappaB ligand. Infect Immun 2003;71:6019-6026.
52. Bowers MR, Fisher LW, Termine JD, Somerman MJ. Connective tissue-associated proteins in crevicular fluid: Potential markers for periodontal diseases. J Periodontol 1989;60:448-451.
53. Talonpoika JT, Hamalainen MM. Type I collagen carboxyterminal telopeptide in human gingival crevicular fluid in different clinical conditions and after periodontal treatment. J Clin Periodontol 1994;21:320-326.
54. Golub LM, Lee HM, Greenwald RA, et al. A matrix metalloproteinase inhibitor reduces bone-type collagen degradation fragments and specific collagenases in gingival crevicular fluid during adult periodontitis. Inflamm Res 1997;46:310-319.
55. Palys MD, Haffajee AD, Socransky SS, Giannobile WV. Relationship between C-telopeptide pyridinoline cross-links (ICTP) and putative periodontal pathogens in periodontitis. J Clin Periodontol 1998;25:865-871.
56. Giannobile WV. C-telopeptide pyridinoline cross-links. Sensitive indicators of periodontal tissue destruction. Ann N Y Acad Sci 1999;878:404-412.
57. Oringer RJ, Al-Shammari KF, Aldredge WA, et al. Effect of locally delivered minocycline microspheres on markers of bone resorption. J Periodontol 2002;73:835-842.
58. Al-Shammari KF, Giannobile WV, Aldredge WA, et al. Effect of non-surgical periodontal therapy on C-telopeptide pyridinoline cross-links (ICTP) and interleukin-1 levels. J Periodontol 2001;72:1045-1051.
59. Bartold PM, Marshall RI, Haynes DR. Periodontitis and rheumatoid arthritis: A review. J Periodontol 2005;76:2066-2074.
60. Haynes DR. Bone lysis and inflammation. Inflamm Res 2004;53:596-600.
61. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986;319:516-518.
62. Katagiri T, Takahashi N. Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 2002;8:147-159.
63. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-alpha induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000;275:4858-4864.
64. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000;191:275-286.
65. Wozniak KL, Arribas A, Leigh JE, Fidel PL Jr. Inhibitory effects of whole and parotid saliva on immunomodulators. Oral Microbiol Immunol 2002;17:100-107.
66. Ino T, Tada A, Tominaga A, Komori Y, Chiba H, Senpuku H. Role of salivary tumour necrosis factor alpha in HIV-positive patients with oral manifestations. Int J STD AIDS 2007;18:565-569.
67. Rhodus NL, Cheng B, Bowles W, Myers S, Miller L, Ondrey F. Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone. Oral Dis 2006;12:112-116.
68. Rhodus NL, Cheng B, Myers S, Miller L, Ho V, Ondrey F. The feasibility of monitoring NF-kappaB associated cytokines: TNF-alpha, IL-1alpha, IL-6, and IL-8 in whole saliva for the malignant transformation of oral lichen planus. Mol Carcinog 2005;44:77-82.
69. Rhodus NL, Ho V, Miller CS, Myers S, Ondrey F. NF-kappaB dependent cytokine levels in saliva of patients with oral preneoplastic lesions and oral squamous cell carcinoma. Cancer Detect Prev 2005;29:42-45.
70. Boras VV, Lukac J, Brailo V, Picek P, Kordic D, Zilic IA. Salivary interleukin-6 and tumor necrosis factor-alpha in patients with recurrent aphthous ulceration. J Oral Pathol Med 2006;35:241-243.